A longer shutdown at FDA could put anticipated new drugs in jeopardy

A longer shutdown at FDA could put anticipated new drugs in jeopardy

If the shutdown drags on at FDA, it will put anticipated new treatments in jeopardy

By NICHOLAS FLORKO AND IKE SWETLITZ

MICHAEL REYNOLDS/EPA

The agency only has about three more weeks’ worth of funding to draw down, after which it would have to suspend new drug approvals.

READ MORE